Cassava Sciences, Inc. Warrant (SAVAW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cassava Sciences, Inc. Warrant (SAVAW) trades at $0.03 with AI Score 44/100 (Grade C). Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing drugs for neurodegenerative diseases, particularly Alzheimer's disease. Market cap: $1.45M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SAVAW: SAVAW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SAVAW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SAVAW: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Cassava Sciences, Inc. Warrant (SAVAW) Healthcare & Pipeline Overview
Cassava Sciences, Inc. is a clinical-stage biotechnology firm specializing in neurodegenerative disease therapeutics, primarily targeting Alzheimer's with its simufilam drug candidate and SavaDx diagnostic. The company operates in a competitive biotech landscape, focusing on innovative solutions for unmet medical needs in aging populations.
What Is the Investment Thesis for SAVAW?
Cassava Sciences presents a high-risk, high-reward investment opportunity centered on its lead drug candidate, simufilam, for Alzheimer's disease. The successful completion of ongoing clinical trials and subsequent regulatory approval could drive significant value. The company's SavaDx diagnostic also offers potential upside. Key value drivers include positive clinical trial data for simufilam, partnerships with larger pharmaceutical companies, and successful commercialization of SavaDx. The company's small size and limited resources pose risks, as does the inherent uncertainty of drug development. The company's negative ROE of -82.7% and a market cap of $1.45M also indicate financial challenges. Upcoming clinical trial results will be a critical catalyst.
Based on FMP financials and quantitative analysis
SAVAW Key Highlights
Lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial
- Investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease
- The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019
- The company has a negative ROE of -82.7%
- The company has a Free Cash Flow of $0.02B
Who Are SAVAW's Competitors?
SAVAW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASLN ASLN | $0.60 | -14.27% | $777M | 56 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SAVAW's Key Strengths?
Novel drug candidate (simufilam) with a unique mechanism of action.
- Potential for early diagnosis of Alzheimer's disease with SavaDx.
- Experienced management team with expertise in drug development.
- Focus on a large and underserved market.
What Are SAVAW's Weaknesses?
Limited financial resources.
- Dependence on the success of a single drug candidate.
- Small company size with limited infrastructure.
- High risk of clinical trial failure.
What Could Drive SAVAW Stock Higher?
Announcement of Phase 3 clinical trial results for simufilam.
- Regulatory submission for SavaDx diagnostic.
- Potential partnerships with larger pharmaceutical companies.
- Grant funding opportunities for research and development.
What Are the Key Risks for SAVAW?
Clinical trial failure of simufilam.
- Regulatory delays or rejection of SavaDx.
- Competition from other companies developing Alzheimer's treatments.
- Limited financial resources to support research and development.
- Negative publicity or controversies surrounding the company's research.
What Are the Growth Opportunities for SAVAW?
- Advancement of Simufilam through Clinical Trials: Cassava Sciences' primary growth opportunity lies in the successful advancement of simufilam through Phase 3 clinical trials and subsequent FDA approval. The Alzheimer's disease market is vast, with millions of patients worldwide and limited effective treatments. Positive clinical trial results could lead to significant market share and revenue generation. The timeline for this growth opportunity is dependent on the progress and outcomes of the ongoing clinical trials, with potential for commercialization within the next 3-5 years.
- Commercialization of SavaDx Diagnostic: The development and commercialization of SavaDx, a blood-based diagnostic for Alzheimer's disease, represents another significant growth opportunity. Early and accurate diagnosis of Alzheimer's is crucial for effective treatment and patient management. SavaDx has the potential to become a widely adopted diagnostic tool, generating revenue through sales to hospitals, clinics, and research institutions. The timeline for this growth opportunity is contingent on successful clinical validation and regulatory approval, with potential for market entry within the next 2-3 years.
- Partnerships and Collaborations: Cassava Sciences can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its products. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its therapies to market. The timing and success of these partnerships are uncertain, but they could significantly impact the company's growth trajectory.
- Expansion into Other Neurodegenerative Diseases: While currently focused on Alzheimer's disease, Cassava Sciences could expand its research and development efforts to target other neurodegenerative diseases, such as Parkinson's disease and frontotemporal dementia. This would broaden the company's product pipeline and market opportunities. The timeline for this expansion is dependent on the company's financial resources and the success of its current programs.
- Government Funding and Grants: Cassava Sciences can pursue government funding and grants to support its research and development activities. Government funding can provide non-dilutive capital, reducing the company's reliance on private investors and preserving shareholder value. The availability and success of grant applications are uncertain, but they represent a potential source of funding for the company's growth initiatives.
What Are SAVAW's Competitive Advantages?
- Proprietary drug candidates with unique mechanisms of action.
- Intellectual property protection through patents.
- First-mover advantage in developing novel Alzheimer's treatments.
- Expertise in neurodegenerative disease research and development.
What Does SAVAW Do?
Cassava Sciences, Inc. was founded in 1998 and is headquartered in Austin, Texas. Initially incorporated as Pain Therapeutics, Inc., the company rebranded to Cassava Sciences, Inc. in March 2019, signaling a strategic shift towards neurodegenerative diseases. The company's primary focus is on developing novel treatments and diagnostics for Alzheimer's disease. Their lead therapeutic product candidate, simufilam, is a small molecule drug that has completed a Phase 2b clinical trial. Simufilam is designed to restore the normal shape and function of altered filamin A protein in the brain, which is believed to be a key factor in Alzheimer's disease pathology. In addition to simufilam, Cassava Sciences is also developing SavaDx, an investigational blood-based biomarker diagnostic to detect Alzheimer's disease, potentially allowing for earlier and more accurate diagnosis. The company operates within the highly competitive biotechnology industry, facing challenges related to clinical trial success, regulatory approvals, and securing funding for research and development. Cassava Sciences currently has 30 employees.
What Products and Services Does SAVAW Offer?
- Develop drugs for neurodegenerative diseases.
- Focus on Alzheimer's disease therapeutics.
- Develop small molecule drugs.
- Conduct clinical trials for their drug candidates.
- Develop blood-based diagnostics for Alzheimer's disease.
- Research and develop novel treatments for neurological disorders.
How Does SAVAW Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of approved drugs and diagnostics.
- Partner with pharmaceutical companies for development and distribution.
- Secure funding through grants, collaborations, and private investment.
What Industry Does SAVAW Operate In?
Cassava Sciences operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The Alzheimer's disease market is a significant area of focus due to the growing aging population and the lack of effective treatments. The competitive landscape includes companies like ASLN, CWBR, CYTO, NAYA, and NBSE, all vying to develop innovative therapies for neurodegenerative diseases. The industry is driven by scientific advancements, regulatory changes, and the increasing demand for novel therapeutics.
Who Are SAVAW's Key Customers?
- Patients with Alzheimer's disease.
- Hospitals and clinics.
- Research institutions.
- Pharmaceutical companies (potential partners).
Company Profile
Cassava Sciences, Inc. Warrant operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Richard Jon Barry. SAVAW has traded publicly since 2024.
SAVAW Valuation & Market Position
Relative to its peer group, SAVAW's quantitative score of 44/100 is below the peer average of 71/100.
SAVAW Financials
Bull Case vs Bear Case
Bull Case
- Novel drug candidate (simufilam) with a unique mechanism of action.
- Potential for early diagnosis of Alzheimer's disease with SavaDx.
- Experienced management team with expertise in drug development.
- Focus on a large and underserved market.
Bear Case
- Limited financial resources.
- Dependence on the success of a single drug candidate.
- Small company size with limited infrastructure.
- High risk of clinical trial failure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SAVAW Latest News
No recent news available for SAVAW.
SAVAW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SAVAW.
Price Targets
Wall Street price target analysis for SAVAW.
SAVAW MoonshotScore
What does this score mean?
The MoonshotScore rates SAVAW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Richard Jon Barry
CEO
Richard Jon Barry serves as the CEO of Cassava Sciences, leading a team of 30 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions at various companies, overseeing clinical trials, regulatory submissions, and market launches. Barry's expertise spans multiple therapeutic areas, including neurology and oncology. He is responsible for guiding Cassava Sciences' strategic direction and driving the development of its Alzheimer's disease therapies.
Track Record: Under Richard Jon Barry's leadership, Cassava Sciences has focused on advancing simufilam through clinical trials and developing SavaDx as a diagnostic tool. Key milestones include the completion of Phase 2b clinical trial for simufilam. Barry has also overseen the company's efforts to secure funding and partnerships to support its research and development programs. His strategic decisions have been instrumental in shaping Cassava Sciences' focus on Alzheimer's disease.
SAVAW Healthcare Stock FAQ
What does the AI Score mean for SAVAW?
SAVAW holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing drugs for neurodegenerative diseases, particularly Alzheimer's disease. Their lead therapeutic candidate is …
What does Cassava Sciences, Inc. Warrant do?
Cassava Sciences, Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's lead therapeutic candidate, simufilam, is a small molecule drug designed to restore the normal shape and function of altered filamin A protein in the brain.
What are the main risks for SAVAW?
The primary risks for Cassava Sciences, Inc. Warrant revolve around the uncertainty inherent in clinical-stage biotechnology companies. The success of simufilam, their lead drug candidate, is not guaranteed, and clinical trial failures could significantly impact the company's valuation. Regulatory hurdles and potential delays in the approval process for both simufilam and SavaDx also pose risks.
What are the key factors to evaluate for SAVAW?
Cassava Sciences, Inc. Warrant (SAVAW) holds an AI score of 44/100 (low). Cassava Sciences presents a high-risk, high-reward investment opportunity centered on its lead drug candidate, simufilam, for Alzheimer's disease. Not financial advice.
How frequently does SAVAW data refresh on this page?
SAVAW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SAVAW's recent stock price performance?
Cassava Sciences, Inc. Warrant (SAVAW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidate (simufilam) with a unique mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SAVAW overvalued or undervalued right now?
Cassava Sciences, Inc. Warrant (SAVAW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SAVAW before investing?
Before investing in Cassava Sciences, Inc. Warrant (SAVAW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SAVAW to a portfolio?
Key strength of Cassava Sciences, Inc. Warrant (SAVAW): Novel drug candidate (simufilam) with a unique mechanism of action. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.